A Prospective Study of Cutaneous Abnormalities in Patients with Chronic Kidney Disease

Total Page:16

File Type:pdf, Size:1020Kb

A Prospective Study of Cutaneous Abnormalities in Patients with Chronic Kidney Disease Original Article A prospective study of cutaneous abnormalities in patients with chronic kidney disease E. A. Thomas, B. Pawar1, A. Thomas Departments of Dermatology, and 1Nephrology, Christian Medical College and Hospital, Ludhiana, Punjab, India ABSTRACT There are diverse ways in which the skin is affected by chronic kidney disease (CKD). Various specific and nonspecific skin abnormalities are observed in patients with CKD. The aim of the study was to document the prevalence of skin diseases that commonly occur in patients with CKD on medical treatment and dialysis. A total of 99 patients with CKD were examined for evidence of skin diseases. Ninety-six had at least one cutaneous abnormality attributable to CKD. The most prevalent finding was xerosis (66.7%), followed by pallor (45.45%), pruritus (43.4%), and cutaneous pigmentation (32.3%). Other cutaneous manifestations included dermatitis (27.27%); Kyrle’s disease (17.17%); fungal (8.08%), bacterial (11.1%), and viral (5.05%) infections; purpura (10.1%); gynecomastia (4.04%); and yellow skin (5.05%). The common nail changes were half and half nails (36.36%) and onycholysis (13.13%). CKD is associated with various cutaneous abnormalities caused either by the disease or by treatment, the most common being xerosis and pruritus. The dermatologic complications can significantly impair the quality of life in certain individuals; therefore, earlier diagnosis and treatment is important to improve their quality of life. Key words: Chronic kidney disease, dialysis, uremic pruritus Introduction Materials and Methods Dermatologic abnormalities are common in chronic Patients with CKD, on medical treatment or dialysis kidney disease (CKD) and range from the nearly were included in this prospective, observational study. universal xerosis and pruritus to uncommon conditions The history of duration of CKD and dialysis as well as such as hyperpigmentation of exposed areas, purpuric the onset of skin disease with regard to diagnosis of skin changes, acquired perforating dermatosis, and nail CKD were taken. A complete clinical and dermatological abnormalities.[1] In a study by Pico et al.,[2] all patients examination was carried out. The creatinine clearance of with CKD had one or more skin manifestations, while these patients was calculated using the Crockroft–Gault Bencini et al.[3] noticed skin changes in 79% of the formula.[4] patients. This study was conducted to determine the prevalence of cutaneous abnormalities in stable and Staging of CKD was done according to the Kidney Disease dialysis‑dependent CKD patients. Outcomes Quality Initiative (K/DOQI) clinical practice guidelines.[5] Address for correspondence: Dr. Emy Abi Thomas, Department of Dermatology, Christian In all patients, a complete blood count; renal function Medical College and Hospital, Ludhiana, Punjab - 141 008, India. tests such as blood urea, serum creatinine and electrolytes, E-mail: [email protected] serum calcium, inorganic phosphorus, and alkaline phosphatase; urine analysis and renal ultrasound were Access this article online performed. Specific investigations such as skin biopsies, Quick Response Code: Website: culture and sensitivity for bacterial infections, Gram’s www.indianjnephrol.org stain, potassium hydroxide mount, and fungal culture were done wherever clinically indicated. DOI: 10.4103/0971-4065.97127 The severity of xerosis was assessed using a modified version of grading used by Morton:[6] Grade‑ 0 (smooth skin), 116 March 2012 / Vol 22 / Issue 2 Indian Journal of Nephrology Thomas, et al.: Skin disorders in chronic kidney disease grade‑ 1 (rough skin), and grade‑ 2 (rough skin with scaling). Table 1: Cutaneous manifestations in different stages of chronic kidney disease Patients with CKD stage V were further classified as either Skin III IV V V V Total Percentage manifestations stable CAPD HD stable CKD, hemodialysis‑dependent CKD (HD‑CKD), and Xerosis on continuous ambulatory peritoneal dialysis (CAPD). Mild (grade‑I) 3 6 3 3 36 51 66.7 Renal transplant recipients were excluded from this Severe (grade II) 2 2 1 1 9 15 43.4 prospective observational study. Pruritus Mild 3 4 1 1 17 26 45.45 Severe 2 2 0 1 12 17 32.3 Results Pallor ‑ 2 4 1 38 45 5.05 Pigmentation ‑ 1 1 1 29 32 10.1 Of the 99 patients, 78 were males. By staging the Yellow skin ‑ ‑ 1 ‑ 4 5 17.7 Purpura ‑ 1 2 ‑ 7 10 4.04 severity of CKD according to the K/DOQI clinical practice Kyrle’s disease 1 ‑ 1 3 12 17 11.1 guidelines,[5] 1 patient was found to be in stage II, 8 in Gynecomastia ‑ ‑ ‑ ‑ 4 4 5.05 stage III, 10 in stage IV, and 80 in stage V. Stage V patients Infections were further divided into stable (6), HD‑CKD (70), and Bacterial 2 2 ‑ 2 5 11 8.08 Viral ‑ ‑ ‑ 1 4 5 1.01 CAPD (4). There were no patients with stage I CKD. Most Fungal 3 2 ‑ 1 2 8 1.01 of the patients were in the age group of 40‑60 years, Parasitic ‑ ‑ ‑ ‑ 1 1 27.27 with a mean age of 50.5 years. The youngest patient was Mycobacterium Lupus vulgaris ‑ ‑ ‑ ‑ 1 1 11 years old and the eldest, 86 years old. The etiology Dermatitis 4 4 6 ‑ 13 27 of CKD in this study showed that diabetic nephropathy CAPD = Continuous ambulatory peritoneal dialysis, HD = Hemodialysis was the cause of CKD in 42 patients followed by chronic interstitial nephritis (18), chronic glomerulonephritis Table 2: Nail changes in different stages of chronic (14), hypertension (5), autosomal dominant polycystic kidney disease kidney disease (6), obstruction (6), amyloidosis (2), and Nail changes III IV V V V Total Percentage undetermined etiology in 6 patients. stable CAPD HD Half and half nail 5 3 2 1 25 36 36.36 A total of 10 patients (9 male and 1 female) were Onycholysis 2 ‑ ‑ 2 9 13 13.13 Onychomycosis 2 2 ‑ 1 2 7 7.07 Hepatitis C Virus (HCV) antibody‑positive and 2 (2 male) Pitting 1 1 ‑ 1 4 7 7.07 were Hepatitis B Surface Antigen (HBsAg) positive. Mee’s line 1 ‑ ‑ 1 6 8 8.08 Anemia was a common problem when these patients Beau’s line ‑ 2 ‑ ‑ 3 5 5.05 were first seen, 7 had hemoglobin levels of less than Koilonychia ‑ ‑ ‑ ‑ 5 5 5.05 Subungual ‑ ‑ 1 ‑ 5 6 6.06 5 g/dl, 54 patients had hemoglobin levels in the range hyperkeratosis of 5‑8 g/dl and 38 had greater than 8 g/dl. In this study, Clubbing 2 ‑ ‑ ‑ 2 4 4.04 96 patients had at least one cutaneous abnormality; Muehrcke’s line ‑ ‑ ‑ ‑ 3 3 3.03 Brown nail bed arc ‑ ‑ ‑ ‑ 4 4 4.04 42 had multiple skin lesions, whereas 3 patients did Splinter ‑ ‑ 1 ‑ ‑ 1 1.01 not have any symptoms and signs of skin disease. Skin hemorrhage abnormalities in relation to staging of CKD are shown CAPD = Continuous ambulatory peritoneal dialysis, HD = Hemodialysis in Table 1. line (3.03%), brown nail bed arc (4.04%), and Splinter One patient on hemodialysis developed bullous hemorrhage (1.01%). dermatosis of hemodialysis. Other skin lesions seen in patients with CKD were diabetic bullae (1), diabetic Oral mucosa changes seen in this study were macroglossia dermopathy (1), psoriasis (2), vitiligo (1), acanthosis with teeth markings (tongue sign of uremia) in 9 (9.09%) nigricans (2), Darier’s disease (1), neurofibromatosis (1), of the patients; of this 22.22% were in stage IV and and Schamberg’s disease (1). 77.79% in stage V. Other mucosal changes were angular cheilitis (5.05%), ulcerative stomatitis (2.02%), and Nail changes in CKD are shown in Table 2. Among xerostomia (5.05%). the nail changes observed, Lindsay’s nails (half and half nails) were the most common and were seen in Discussion 36 patients (36.36%). Other nail changes included onycholysis (13.13%), onychomycosis (7.07%), and Xerosis was the most common cutaneous abnormality Mee’s lines (8.08%). Beau’s lines (5.05%), koilonychia (66.7%), which is comparable with other studies.[7‑10] This (5.05%), subungual hyperkeratosis (6.06%), Muehrcke’s abnormality was observed mainly in patients who were on Indian Journal of Nephrology March 2012 / Vol 22 / Issue 2 117 Thomas, et al.: Skin disorders in chronic kidney disease maintenance hemodialysis (45.45%); this being similar reported that pigmentary alterations occurred in 25‑70% to Anderson et al.,[11] who reported a high frequency of of dialysis patients and increases over the duration of renal xerosis (50‑70%) in dialysis patients [Figure 1]. None of disease. The pigmentation on sun‑exposed areas has been the patients had xerosis from childhood, but one patient attributed to an increase in melanin in the basal layer had hypothyroidism prior to the diagnosis of CKD. of the epidermis due to an increase in poorly dialyzable Features of atopy, associated with dry skin and keratosis beta‑melanocyte–stimulating hormone.[19] The intensity pilaris‑like lesions were seen in eight patients. A reduction of melanin pigmentation increases with respect to the in the size and functional abnormality of eccrine sweat duration of end‑stage renal disease. A yellowish tinge of the glands, suggesting compromised eccrine secretion skin was reported in 40% of patients by Pico et al.,[2] but leading to epithelial dehydration[12] may contribute to we encountered yellowish discoloration in only 5 (5.05%) the development of xerosis. patients, probably because of the dark complexion of Indians, which masks this finding. The yellowish skin color Pruritus is one of the most characteristic and annoying has been attributed to retained lipid soluble pigments such symptoms of CKD. In this study, 43.4% of patients as lipochromes and carotenoids, which are deposited in complained of pruritus, a finding similar to that in a study the dermis and subcutaneous tissue.[20] by Udayakumar et al., where they found the prevalence of [9] pruritus to be 53%.
Recommended publications
  • Itch in Ethnic Populations
    Acta Derm Venereol 2010; 90: 227–234 REVIEW ARTICLE Itch in Ethnic Populations Hong Liang TEY1 and Gil YOSIPOVITCH2 1National Skin Centre, 1, Mandalay Road, Singapore, Singapore, and 2Department of Dermatology, Neurobiology & Anatomy, and Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USA Racial and ethnic differences in the prevalence and clini- DIFFERENCES IN SKIN BIOLOGY AND ITCH cal characteristics of itch have rarely been studied. The aim of this review is to highlight possible associations Few studies have examined the differences between between ethnicity and different forms of chronic itch. We skin types in relation to ethnicity and neurobiology of provide a current review of the prevalence of different the skin. Differences between ethnic skin types and types of itch in ethnic populations. Genetic variation may skin properties may explain racial disparities seen in significantly affect receptors for itch as well as response pruritic dermatologic disorders. to anti-pruritic therapies. Primary cutaneous amyloido- sis, a type of pruritic dermatosis, is particularly common Epidermal structure and function in Asians and rare in Caucasians and African Ameri- cans, and this may relate to a genetic polymorphism in A recent study has shown that the skin surface and the Interleukin-31 receptor. Pruritus secondary to the melanocyte cytosol of darkly pigmented skin is more use of chloroquine for malaria is a common problem for acidic compared with those of type I–III skin (1). Serine African patients, but is not commonly reported in other protease enzymes, which have significant roles as pruri- ethnic groups. In patients with primary biliary cirrho- togens in atopic eczema and other chronic skin diseases, sis, pruritus is more common and more severe in African have been shown to be significantly reduced in black Americans and Hispanics compared with Caucasians.
    [Show full text]
  • Dermatologia 2021;96(4):397---407
    Anais Brasileiros de Dermatologia 2021;96(4):397---407 Anais Brasileiros de Dermatologia www.anaisdedermatologia.org.br CONTINUING MEDICAL EDUCATION Phototherapyଝ,ଝଝ ∗ Norami de Moura Barros , Lissiê Lunardi Sbroglio , Maria de Oliveira Buffara , Jessica Lana Conceic¸ão e Silva Baka , Allen de Souza Pessoa , Luna Azulay-Abulafia Department of Dermatology, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil Received 3 December 2019; accepted 2 March 2021 Available online 2 April 2021 Abstract Of all the therapeutic options available in Dermatology, few of them have the his- KEYWORDS tory, effectiveness, and safety of phototherapy. Heliotherapy, NB-UVB, PUVA, and UVA1 are Phototherapy; currently the most common types of phototherapy used. Although psoriasis is the most frequent PUVA therapy; indication, it is used for atopic dermatitis, vitiligo, cutaneous T-cell lymphoma, and cutaneous Ultraviolet therapy sclerosis, among others. Before indicating phototherapy, a complete patient assessment should be performed. Possible contraindications should be actively searched for and it is essential to assess whether the patient can come to the treatment center at least twice a week. One of the main method limitations is the difficulty that patients have to attend the sessions. This therapy usually occurs in association with other treatments: topical or systemic medications. Maintaining the regular monitoring of the patient is essential to identify and treat possible adverse effects. Phototherapy is recognized for its benefits and should be considered whenever possible. © 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana,˜ S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
    [Show full text]
  • European Guideline Chronic Pruritus Final Version
    EDF-Guidelines for Chronic Pruritus In cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS) E Weisshaar1, JC Szepietowski2, U Darsow3, L Misery4, J Wallengren5, T Mettang6, U Gieler7, T Lotti8, J Lambert9, P Maisel10, M Streit11, M Greaves12, A Carmichael13, E Tschachler14, J Ring3, S Ständer15 University Hospital Heidelberg, Clinical Social Medicine, Environmental and Occupational Dermatology, Germany1, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland2, Department of Dermatology and Allergy Biederstein, Technical University Munich, Germany3, Department of Dermatology, University Hospital Brest, France4, Department of Dermatology, Lund University, Sweden5, German Clinic for Diagnostics, Nephrology, Wiesbaden, Germany6, Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany7, Department of Dermatology, University of Florence, Italy8, Department of Dermatology, University of Antwerpen, Belgium9, Department of General Medicine, University Hospital Muenster, Germany10, Department of Dermatology, Kantonsspital Aarau, Switzerland11, Department of Dermatology, St. Thomas Hospital Lambeth, London, UK12, Department of Dermatology, James Cook University Hospital Middlesbrough, UK13, Department of Dermatology, Medical University Vienna, Austria14, Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany15 Corresponding author: Elke Weisshaar
    [Show full text]
  • Update of the Guideline on Chronic Pruritus
    Update of the Guideline on Chronic Pruritus Developed by the Guideline Subcommittee “Chronic Pruritus” of the European Dermatology Forum Subcommittee Members: Prof. Dr. Elke Weisshaar, Heidelberg (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Erwin Tschachler, Wien (Austria) Prof. Dr. Torello Lotti, Florence (Italy) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Laurent Misery, Brest (France) Dr. Markus Streit, Aarau (Switzerland) Prof. Dr. Thomas Mettang, Wiesbaden (Germany) Prof. Dr. Jacek Szepietowski, Wroclaw (Poland) Prof. Dr. Joanna Wallengren, Lund (Sweden) Dr. Peter Maisel, Münster (Germany) Prof. Dr. Uwe Gieler, Gießen (Germany) Prof. Dr. Malcolm Greaves (Singapore) Prof. Dr. Ulf Darsow, Munich (Germany) Prof. Dr. Julien Lambert, Antwerp (Belgium) Members of EDF Guideline Committee: Prof. Dr. Werner Aberer, Graz (Austria) Prof. Dr. Dieter Metze, Münster (Germany) Prof. Dr. Martine Bagot, Paris (France) Dr. Kai Munte, Rotterdam (Netherlands) Prof. Dr. Nicole Basset-Seguin, Paris (France) Prof. Dr. Gilian Murphy, Dublin (Ireland) Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany) Prof. Dr. Martino Neumann, Rotterdam (Netherlands) Prof. Dr. Lasse Braathen, Bern (Switzerland) Prof. Dr. Tony Ormerod, Aberdeen (UK) Prof. Dr. Sergio Chimenti, Rome (Italy) Prof. Dr. Mauro Picardo, Rome (Italy) Prof. Dr. Alexander Enk, Heidelberg (Germany) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Claudio Feliciani, Rome (Italy) Prof. Dr. Annamari Ranki, Helsinki (Finland) Prof. Dr. Claus Garbe, Tübingen (Germany) Prof. Dr. Berthold Rzany, Berlin (Germany) Prof. Dr. Harald Gollnick, Magdeburg (Germany) Prof. Dr. Rudolf Stadler, Minden (Germany) Prof. Dr. Gerd Gross, Rostock (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Vladimir Hegyi, Bratislava (Slovakia) Prof. Dr. Eggert Stockfleth, Berlin (Germany) Prof. Dr.
    [Show full text]
  • World Journal of Dermatology
    World Journal of W J D Dermatology Submit a Manuscript: http://www.wjgnet.com/esps/ World J Dermatol 2015 May 2; 4(2): 108-113 Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx ISSN 2218-6190 (online) DOI: 10.5314/wjd.v4.i2.108 © 2015 Baishideng Publishing Group Inc. All rights reserved.V MINIREVIEWS New innovation of moisturizers containing non-steroidal anti-inflammatory agents for atopic dermatitis Montree Udompataikul Montree Udompataikul, Skin Center, Srinakharinwirot experience. These moisturizers might be considered University, Bangkok 10110, Thailand as an alternative treatment in acute flare of mild to Author contributions: Udompataikul M contributed to this moderate atopic dermatitis. work. Conflict-of-interest:None. Key words: Non-steroidal anti-inflammatory agents; Open-Access: This article is an open-access article which was Moisturizer; Atopic dermatitis selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, © The Author(s) 2015. Published by Baishideng Publishing which permits others to distribute, remix, adapt, build upon this Group Inc. All rights reserved. work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and Core tip: The skin care management particular moisturizers the use is non-commercial. See: http://creativecommons.org/ play an important role in atopic dermatitis. The side effects licenses/by-nc/4.0/ of corticosteroids are limited in their use in this disease. Correspondence to: Montree Udompataikul, MD, Associate Take together, a new moisturizer containing various anti- Prefessor, Skin Center, Srinakharinwirot University, Sukhumvit 23, Wattana, Bangkok 10110, Thailand.
    [Show full text]
  • Pruritus Associated with Chronic Kidney Disease: a Comprehensive Literature Review
    Open Access Review Article DOI: 10.7759/cureus.5256 Pruritus Associated With Chronic Kidney Disease: A Comprehensive Literature Review Sanzida S. Swarna 1 , Kashif Aziz 2 , Tayyaba Zubair 3 , Nida Qadir 4 , Mehreen Khan 5 1. Internal Medicine, Sir Salimullah Medical College, Dhaka, BGD 2. Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA 3. Internal Medicine, Desai Medical Center, Ellicott City, MD, USA 4. Internal Medicine, Liaquat University of Medical and Health Sciences, Liaquat University Hospital Jamshoro, Hyderabad, PAK 5. Internal Medicine, George Washington University School of Medicine and Health Sciences, Washington DC, USA Corresponding author: Kashif Aziz, [email protected] Abstract The prevalence of pruritus in chronic kidney disease (CKD) patients has varied over the years, and some studies suggest the prevalence may be coming down with more effective dialysis. Chronic kidney disease- associated pruritus (CKD-aP), previously called uremic pruritus, is a distressing symptom experienced by patients with mainly advanced chronic kidney disease. CKD-aP is associated with poor quality of life, depression, anxiety, sleep disturbance, and increased mortality. The incidence of CKD-aP is decreasing given improvements in dialysis treatments, but approximately 40% of patients with end-stage renal disease experience CKD-aP. While the pathogenesis of CKD-aP is not well understood, the interaction between non- myelinated C fibers and dermal mast cells plays an important role in precipitation and sensory stimulation. Other causes of CKD-aP include metabolic abnormalities such as abnormal serum calcium, parathyroid, and phosphate levels; an imbalance in opiate receptors is also an important factor. CKD-aP usually presents as large symmetric reddened areas of skin, often at night.
    [Show full text]
  • Views in Allergy and Immunology
    CLINICAL REVIEWS IN ALLERGY AND IMMUNOLOGY Dermatology for the Allergist Dennis Kim, MD, and Richard Lockey, MD specific laboratory tests and pathognomonic skin findings do Abstract: Allergists/immunologists see patients with a variety of not exist (Table 1). skin disorders. Some, such as atopic and allergic contact dermatitis, There are 3 forms of AD: acute, subacute, and chronic. are caused by abnormal immunologic reactions, whereas others, Acute AD is characterized by intensely pruritic, erythematous such as seborrheic dermatitis or rosacea, lack an immunologic basis. papules associated with excoriations, vesiculations, and se- This review summarizes a select group of dermatologic problems rous exudates. Subacute AD is associated with erythematous, commonly encountered by an allergist/immunologist. excoriated, scaling papules. Chronic AD is associated with Key Words: dermatology, dermatitis, allergy, allergic, allergist, thickened lichenified skin and fibrotic papules. There is skin, disease considerable overlap of these 3 forms, especially with chronic (WAO Journal 2010; 3:202–215) AD, which can manifest in all 3 ways in the same patient. The relationship between AD and causative allergens is difficult to establish. However, clinical studies suggest that extrinsic factors can impact the course of disease. Therefore, in some cases, it is helpful to perform skin testing on foods INTRODUCTION that are commonly associated with food allergy (wheat, milk, llergists/immunologists see patients with a variety of skin soy, egg, peanut, tree nuts, molluscan, and crustaceous shell- Adisorders. Some, such as atopic and allergic contact fish) and aeroallergens to rule out allergic triggers that can dermatitis, are caused by abnormal immunologic reactions, sometimes exacerbate this disease.
    [Show full text]
  • Epidemiology of Itch: Adding to the Burden of Skin Morbidity
    Acta Derm Venereol 2009; 89: 339–350 REVIEW ARTICLE Epidemiology of Itch: Adding to the Burden of Skin Morbidity Elke WEISSHAAR1 and Florence DALGARD2 1Department of Clinical Social Medicine, Occupational and Environmental Dermatology, University Hospital Heidelberg, Germany, 2Institute of General Practice and Community Medicine, University of Oslo, Norway, and Judge Baker Children Center, Harvard Medical School, Boston, MA, USA Itch is the most frequent symptom in dermatology and disease with environmental factors, to meet demand has been researched more extensively in recent years. and to investigate factors of importance in preventing Nevertheless, there are few true epidemiological studies disease in the population (2–4). Individuals presenting on itch. The aim of this paper is to review the current to doctors tend to have more severe disease, thus this state of research on the epidemiology of chronic itch in patient population represents the tip of the iceberg re- Western and non-Western populations. The electronic lative to ill-health at the community level (3, 5). databases PubMed, Medline and the Cochrane Library The aim of this paper is to review current knowledge were searched. Conference proceedings and national and of the distribution of chronic itch in different popula- international studies were included. It is difficult to com- tions. The electronic databases PubMed, Medline and pare existing studies due to differing methodology and the Cochrane Library were searched. The search terms lack of standardized measures. The symptom of itch is used were: itch, itching, and pruritus, plus all of these a challenge, not only to clinicians, but also within the terms in combination with dermatology, epidemiology, structure of regional health systems, and with regards community, psycho-social factors, and skin diseases.
    [Show full text]
  • Emerging Research in Chronic Pruritus: from Bedside to Bench and Back Again
    medicines Editorial Emerging Research in Chronic Pruritus: From Bedside to Bench and Back Again Kyle A. Williams and Shawn G. Kwatra * Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-410-955-5933 Received: 21 April 2020; Accepted: 26 April 2020; Published: 29 April 2020 Abstract: This Medicines special issue highlights emerging research spanning from epidemiology to diagnostic workup, pathogenesis, and therapeutics for patients suffering from chronic pruritus. The special issue contains 13 articles reporting relevant epidemiologic and experimental data on chronic pruritus. Keywords: pruritus; itch; treatment; therapeutic; pathogenesis; epidemiology 1. Introduction This editorial serves as an introduction to the special issue “Pathogenesis and Treatment of Chronic Pruritus” and contains an overview of various known causes of chronic pruritus and emerging therapeutics. Chronic pruritus is itch that lasts greater than six weeks and is associated with a variety of dermatologic, systemic, neurologic, and psychiatric etiologies. Itch negatively impacts patient quality of life and has devastating psychosocial consequences. The manuscripts published in this special issue are also a showcase of the current understanding of the pathogenesis of chronic pruritus, along with its epidemiology, diagnostic workup, and therapeutic approaches used to treat chronic pruritus. 2. Epidemiology Chronic pruritus can arise in association with many disease processes and affects many patient populations. Thus, epidemiologic studies are needed to gain a better understanding of the burden of disease. In this special issue, a cross-sectional study of over 18,000 itch patients seen at a tertiary care center showed that African American and female patients were more likely to experience pruritus than their white or male counterparts [1].
    [Show full text]
  • DF Winter 2020-21 28P Webready4
    A DERMATOLOGY FOUNDATION PUBLICATION SPONSORED BY ORTHO DERMATOLOGICS VOL. 39 NOS. 1 & 2 SPECIAL DOUBLE ISSUE WINTER 2020-21 DDEERRMMAATTOOLLOOGGYY ™ Also In This Issue Virtual Seaside Chats FOCUSFOCUS Coming Soon John E. Bournas— New DF Executive Director DF Clinical Symposia: Sun Pharma Award Funds Eye-Opening Proceedings 2020 Research in Autoimmune Disease ADVANCES IN DERMATOLOGY The annual DF Clinical Symposia is a highly regarded 3-day CME event created to share out- standing experts’ knowledge in formal plenary talks, Breakfast Roundtables, and interactive evening Therapeutics Forums. The 2020 Clinical Symposia just preceded the rapid rise of Covid-19 in the U.S. We are pleased to present this most recent Clinical Symposia as a double issue of Dermatology Focus capturing the riches of the plenary talks. The keynote— Melanoma Tumor Syndromes—precedes the 8 symposia: Cancer; Thinking Differently; Therapeutic Updates; Patient Care Pearls; Melanocytic Lesions; Psoriasis; Diagnostics; and Special Populations. Join us for this year’s virtual Clinical Symposia— CDKN2A/CDK4 Tumor Syndrome Seaside Chats—coming in April. • CDKN2A/CDK4: cyclin D-dependent kinases • Inactivating mutations in CDKN2A – Mainly target the p16 transcript – Suggests G1-S restriction is critical in melanoma checkpoint KEYNOTE ADDRESS – Phenotype replicated by activating CDK4 mutations • Mutation carriers: undergo skin exams 4x/year, pancreatic New Insights into Melanoma Tumor Syndromes cancer screening, and stringent sun protection Hensin Tsao, MD Introduction. Investigators are using genetic analysis to progress Known melanoma tumor syndromes. FAMM (CDKN2A/CDK4): toward several predictive goals in melanoma: identifying patients at Tsao discussed a patient in his 20s with substantial freckling, large high risk for developing dysplastic nevi and/or melanoma, identifying dysplastic nevi and many previous excisions, and more than 15 bona melanoma tumors that risk metastasizing, and identifying a given fide melanomas.
    [Show full text]
  • Pathogenesis and Treatment of Chronic Pruritus
    Pathogenesis and of Chronic Treatment Pruritus • Shawn G. Kwatra Pathogenesis and Treatment of Chronic Pruritus Edited by Shawn G. Kwatra Printed Edition of the Special Issue Published in Medicines www.mdpi.com/journal/medicines Pathogenesis and Treatment of Chronic Pruritus Pathogenesis and Treatment of Chronic Pruritus Editor Shawn G. Kwatra MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Editor Shawn G. Kwatra Johns Hopkins University School of Medicine USA Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Medicines (ISSN 2305-6320) (available at: https://www.mdpi.com/journal/medicines/special issues/pathogenesis chronic pruritus). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03943-100-7 (Hbk) ISBN 978-3-03943-101-4 (PDF) c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Editor .............................................. vii Kyle A. Williams and Shawn G. Kwatra Emerging Research in Chronic Pruritus: From Bedside to Bench and Back Again Reprinted from: Medicines 2020, 7, 24, doi:10.3390/medicines7050024 ...............
    [Show full text]
  • Dermatology Today and Tomorrow: from Symptom Control to Targeted Therapy
    DOI: 10.1111/jdv.15335 JEADV REVIEW ARTICLE Dermatology today and tomorrow: from symptom control to targeted therapy U. Blume-Peytavi,1 M. Bagot,2 D. Tennstedt,3 M. Saint Aroman,4,* E. Stockfleth,5 A. Zlotogorski,6 V. Mengeaud,7 A.M. Schmitt,8 C. Paul,9 H.W. Lim,10 V. Georgescu,11 B. Dreno 12 T. Nocera13 1Department of Dermatology and Allergy, Charite-Universit atsmedizin€ Berlin, Berlin, Germany 2Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France 3Department of Dermatology, Saint-Luc University Clinics, Brussels, Belgium 4A-Derma Dermatological Laboratoires, Pierre Fabre Dermo-Cosmetique, Lavaur, France 5Klinik fur€ Dermatologie, Venerologie und Allergologie St. Josef-Hospital, Ruhr-Universitat€ Bochum, Bochum, Germany 6Department of Dermatology, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel 7Ducray Dermatological Laboratories, Pierre Fabre Dermo-Cosmetique, Lavaur, France 8Dermatology Innovation Unit, Pierre Fabre Research and Development Institute, Toulouse, France 9Dermatology Department, Larrey Hospital, UMR INSERM 1065, Paul Sabatier University, Toulouse, France 10Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA 11Avene Dermatological Laboratories, Pierre Fabre Dermo-Cosmetique, Lavaur, France 12Department of Dermato-Oncology, University Hospital, Nantes, France 13Department of Dermatology, Clinical Research and Development Center, Pierre Fabre Dermo-Cosmetique, Toulouse University Hospital, Toulouse, France *Correspondence: M. Saint Aroman. E-mail: [email protected] Abstract For many decades and until recently, medical approach to dermatologic diseases has been based on the physician’s ability to recognize and treat symptoms. Nowadays, advances in the understanding of the biology of diseases and in technologies for intervening against them have allowed physicians to diagnose and treat underlying disease pro- cesses rather than simply addressing the symptoms.
    [Show full text]